Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women, aged 18 years or older.
Documented failure to achieve at least partial response (PR) with, or documented disease progression after, the most recent treatment regimen.
Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy.
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
You may not be if
History of central nervous system lymphoma (either primary or metastatic).
Prior treatment with idelalisib, other selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors, or a pan PI3K inhibitor.
Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of first dose of study treatment.
Active graft-versus-host disease.
Clareo Health | A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
